Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach-Reference-Cited by-同舟云学术

Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach

Published:2017-04-18 Issue:9 Volume:57 Page:1159-1173
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Sun Wan¹,O'Dwyer Peter J.²,Finn Richard S.³,Ruiz-Garcia Ana¹,Shapiro Geoffrey I.⁴,Schwartz Gary K.⁵,DeMichele Angela²,Wang Diane¹

Affiliation:

1. Global Product Development; Pfizer Inc; San Diego CA USA

2. Abramson Cancer Center; Perelman Center for Advanced Medicine; University of Pennsylvania; Philadelphia PA USA

3. David Geffen School of Medicine; Los Angeles CA USA

4. Dana-Farber Cancer Institute; Boston MA USA

5. Columbia University Medical Center; New York NY USA

Funder

Pfizer

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference36 articles.

1. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts;Fry;Mol Cancer Ther,2004

2. PD-0332991 induces G1 arrest of colorectal carcinoma cells through inhibition of the cyclin-dependent kinase-6 and retinoblastoma protein axis;Li;Oncol Lett,2014

3. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity;Logan;Anticancer Res,2013

4. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity;Marzec;Blood,2006

5. Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells;Saab;Mol Cancer Ther,2006

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential association of SULT2A1 and ABCG2 variant alleles with increased risk for palbociclib toxicity;Pharmacogenomics;2024-08-02

2. Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Primary Results From AMEERA-5;Journal of Clinical Oncology;2024-08-01

3. Adverse Event Profiles of CDK4/6 inhibitors: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database;2024-01-02

4. Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial;Journal of Clinical Oncology;2023-11-20

5. Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer;Biomedicine & Pharmacotherapy;2023-11